Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$106.34 USD

106.34
10,687,953

-2.36 (-2.17%)

Updated Oct 21, 2024 04:00 PM ET

After-Market: $106.31 -0.03 (-0.03%) 5:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

LabCorp (LH) to Offer New Test Report for Venom Allergy Testing

LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.

AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use

AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.

Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab

Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

What's in the Offing for Infosys (INFY) This Earnings Season?

The strong demand for the cloud, data analytics, the Internet of Things and security products and solutions amid the ongoing digital transformation wave is likely to have boosted Infosys' (INFY) Q1 performance.

Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings

Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.

Here's Why You Should Retain Chemed (CHE) Stock For Now

Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.

What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?

HCA Healthcare's (HCA) second-quarter results are likely to benefit from better patient volumes. The results might partly suffer from escalating labor costs that might dampen bottom line growth.

GSK Completes Demerger of Consumer Healthcare Business

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

Company News for Jul 19, 2022

Companies in The News Are: SYF,DAL,BA,SGEN,MRK,SBUX

J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance

J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.

Sejuti Banerjea headshot

Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood

JNJ Management expects relatively consistent growth for the rest of the year.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

Strong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.

Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada

Moderna's (MRNA) mRNA-based COVID-19 jab, SpikeVax, receives approval from Health Canada for children aged six months through five years.

AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine

AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.

Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.

Merck and Block have been highlighted as Zacks Bull and Bear of the Day

Merck and Block have been highlighted as Zacks Bull and Bear of the Day.

Benjamin Rains headshot

Bull of the Day: Merck & Co. (MRK)

Merck & Co. (MRK) is a $240 billion market cap pharmaceutical titan that's climbed over 20% in 2022. The firm is continuing to make acquisitions and many of Merck's fundamentals make it an attractive play for the second half of 2022

UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View

UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.

Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M

Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.

J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?

J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds

Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.

Best Growth Stocks to Buy for July 15th

: DLTR, LNTH and MRK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 15, 2022.